| 1 |
34998216 | Radiolabeling of PSMA-617 with 89Zr: A novel use of DMSO to improve radiochemical yield and preliminary small-animal PET results. | 2022 Mar-Apr |
2 |
| 2 |
31919866 | Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer. | 2020 Mar |
1 |
| 3 |
31714783 | Nonradioactive Cell Assay for the Evaluation of Modular Prostate-Specific Membrane Antigen Targeting Ligands via Inductively Coupled Plasma Mass Spectrometry. | 2019 Dec 12 |
1 |
| 4 |
28126683 | PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs. | 2017 Apr |
2 |
| 5 |
29158832 | Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. | 2017 |
2 |
| 6 |
26878194 | Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. | 2016 Mar 10 |
2 |
| 7 |
27553466 | Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. | 2016 Sep |
1 |
| 8 |
24410012 | Heterobivalent agents targeting PSMA and integrin-αvβ3. | 2014 Feb 19 |
1 |
| 9 |
26116124 | Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. | 2014 Dec |
1 |
| 10 |
22369515 | 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. | 2012 Apr 18 |
1 |
| 11 |
15729708 | Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. | 2005 Apr |
3 |